Translate page

English English
en Englishbg Bulgarianzh-CN Chinese (Simplified)hr Croatiancs Czechda Danishnl Dutchfi Finnishfr Frenchde Germanel Greekiw Hebrewhi Hindiid Indonesianit Italianja Japaneseko Koreanmk Macedonianpl Polishpt Portuguesero Romanianru Russiansr Serbiansk Slovaksl Slovenianes Spanishsv Swedishth Thaitr Turkishvi Vietnamese

Virtual Education

Virtual Education Program - COLT Meeting 2017 (Session 5)

 -- Virtual Education Program: 2017 Edition

 

Presentations from a CML Opinion Leader Meeting

We are pleased to make available a new series of presentations from the COLT Meeting 2017, a CML Opinion Leader Training that took place in Adelaide (Australia). Modules currently featured include; frontline CML, TKI resistance/failure, future directions for CML, CML related topics and the CML frontier - all presented by leaders in the field. 

Collage COLT 2017 Session 5

Prof. Timothy Hughes     Dr Agnes Yong

 

 

 
Session 5: The CML frontier
  • Making TFR mainstream 
    (Prof. Timothy Hughes)
  • The immunology of CML and immunomodulation
    (Dr Agnes Yong)

 

 


Timothy Hughes

  

 

Making TFR mainstreamn
Professor Timothy Hughes- SAHMRI / University of Adelaide / Royal Adelaide Hospital

  • TFR in the Australasian CML8 trial of imatinib withdrawal
  • Kaplan-Meier estimate of TFR defined as loss of MMR or defined as loss of CMR
  • Future focus of CML studies: maximising achievement of TFR
  • When to consider a trial of cessation
  • Trial of cessation attempts and TFR based on TKI exposure: Adelaide experience
  • TARGET - Real world data
  • Clinical studies
 

 
Agnes YONG w labcoat1  

The immunology of CML and immunomodulation
Dr Agnes Yong - SAHMRI / SA Pathology, Universities of Adelaide and South Australia

  • Are leukaemia-associated antigen specific T cells relevant in CML?
  • Are NK cells important in CML disease control?
  • Are immune suppressor T regs and MDSCs relevant?
  • Are B cells important in CML?